The genotype of breast cancer (BRC) is considered to be relatively stable during tumor progression, accordingly, determination of the estrogen receptor and HER-2/neu status is currently based on the primary tumor. However, recent data suggest that the gene expression profile of the metastatic ...
Her-2/neu gene amplification and protein expression in primary male breast cancer. The role of HER-2/ neu in male breast cancer is not well defined. The purpose of the current study was to measure the frequency of HER-2/ neu expression in... C Rudlowski,N Friedrichs,A Faridi,... -...
In breast cancer, the predominant genetic mechanism for oncogene activation is through an amplification of a gene. The HER-2 (also known as ErbB2/c-erbB2/ HER-2 / neu ) oncogene is the most frequently amplified oncogene in breast cancer, and its overexpression is associated with poor clinica...
[6] Bui KT, Willson ML, Goel S, et al. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev. 2020. 3(3):CD013538. [7] Sithanandam G, Anderson LM. The ERBB3 receptor in cancer a...
HER-2/neu gene amplification and celt surface overexpression are important factors in breast cancer for prognosis and prediction of sensitivity to anti-HER... Hirsch,R F.,Varella-Garcia,... - 《British Journal of Cancer》 被引量: 198发表: 2002年 Evaluation of HER-2/NEU protein expression ...
In this review, the association of HER-2/neu gene and protein abnormalities with prognosis and response to therapy with trastuzumab and to other therapies in breast cancer is presented. By considering a series of 80 published studies encompassing more than 25,000 patients, the relative advantages ...
Thus, HER1 assessment could reveal a particular breast cancer patient group with probably good response to HER1 targeted therapy. TOP2A gene, encoding topoisomerase II alpha (target for anthracyclines) is predictive of response to anthracycline therapy. TOP2A aberrations (amplification, deletion) are ...
The oncoprotein HER-2 is over-expressed and/or has undergone gene amplification in between 20 to 30% of breast and ovarian cancers. HER-2 amplified breast cancer is associated with a poor prognosis and increased resistance to chemo- and hormonal therapy.
Tissue sections from 10 cases with 2+ and 3+ staining for Her2neu by IHC showed gene amplification in 8 cases. Demonstration of Her-2 neu by IHC, FISH or CISH in FNA is possible and may play a role in the management of patients with advanced breast cancer or those cases where surgical...
a woman is at average risk if she does not have a personal history of breast cancer, a strong family history of breast cancer, or a genetic mutation (change in the structure of a gene) known to increase the risk of breast cancer (such as in a BRCA gene) and has not had chest radia...